About catalent inc. - CTLT
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
CTLT At a Glance
Catalent, Inc.
14 Schoolhouse Road
Somerset, New Jersey 08873
Phone | 1-732-537-6200 | | Revenue | 4.38B |
Industry | Pharmaceuticals: Major | | Net Income | -1,043,000,000.00 |
Sector | Health Technology | | 2024 Sales Growth | 2.768% |
Fiscal Year-end | 06 / 2025 | | Employees | 16,900 |
View SEC Filings
| | | | |
CTLT Valuation
P/E Current | N/A |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | N/A |
Price to Sales Ratio | 2.323 |
Price to Book Ratio | 2.824 |
Price to Cash Flow Ratio | 37.976 |
Enterprise Value to EBITDA | 23.465 |
Enterprise Value to Sales | 3.396 |
Total Debt to Enterprise Value | 0.335 |
CTLT Efficiency
Revenue/Employee | 259,230.769 |
Income Per Employee | -61,715.976 |
Receivables Turnover | 2.798 |
Total Asset Turnover | 0.427 |
CTLT Liquidity
Current Ratio | 2.519 |
Quick Ratio | 1.962 |
Cash Ratio | 0.28 |
CTLT Profitability
Gross Margin | 21.753 |
Operating Margin | 3.31 |
Pretax Margin | -23.442 |
Net Margin | -23.807 |
Return on Assets | -10.161 |
Return on Equity | -25.393 |
Return on Total Capital | -12.139 |
Return on Invested Capital | -11.913 |
CTLT Capital Structure
Total Debt to Total Equity | 138.402 |
Total Debt to Total Capital | 58.054 |
Total Debt to Total Assets | 51.143 |
Long-Term Debt to Equity | 136.709 |
Long-Term Debt to Total Capital | 57.344 |